



ETHOSOME: A Novel permeation enhancer for transdermal drug delivery system

MOHD WAMIQ¹, POPIN KUMAR², SHRADDHA SINGH RAGHAV², DR. PRAVEEN KUMAR ASHOK³

Department of pharmaceuticals, Gyani indersingh institute of professional studies.
Mussoorie Diversion Road Opp. Malsi Deer Park, Dehradun, Uttarakhand, India.

Abstract


It is well established that the structure and function of the skin prevent penetration of many therapeutic molecules to the site of their action in the deep cutaneous strata. The use of nanotechnology has been considerably explored for developing efficient drug delivery systems for topical and transdermal applications. Ethosomes, a nano vesicular carrier designed to overcome the skin barrier (SC), so that new and advanced dermal and indigenous therapies can be achieved. Ethosomes are noninvasive delivery carriers that enable drugs to reach the deep skin layers and/or the systemic circulation. Ethosomes constitute a vesicular nanocarrier containing a relatively high concentration of ethanol (20–45%), water and phospholipid. Ethosomes have higher penetration rate through the skin as compared to liposome's hence these can be used widely in place of liposome's. Ethosomes has enhanced skin permeability, improved drug delivery and increased drug entrapment efficiency etc. Ethosomes having an area of research interest, because of its cross the skin barrier due to ethonilic action and enhanced skin permeation, improved drug delivery, increased drug entrapment efficiency, etc.

Keyword

Ethosome, Transdermal delivery, Nanocarrier vesicle, permeation enhancer.

Introduction

The skin is the largest organ of the human body, calculating for more than 10% of body mass; it permit the body to interact more intimately with its environment^{1,2,3}. Skin forms a protecting covering layer against the external environment and prevents water loss from the underneath tissue. It is more flexibility to resist permanent deformation from movement and thin enough to allow the perception of stimulus. It also performs many ancillary functions such as synthesis and metabolism and the production of sweat enables temperature control and excretion of waste products by means of sweating etc.^{4,5,6} The skin can be considered to be composed of three main layers: subcutaneous tissue, dermis and epidermal layers⁷ shown in **figure 1**



Stratum corneum (Sc) is the outermost layer of the epidermis. It is composed of 10 to 25 layers of dead, elongated, fully keratinized corneocytes, which are sunk in a matrix of lipid bilayers.^{4,8,9} It has been shown that the stratum corneum (Sc) is the main dermal barrier to penetrate through the skin. The limiting factor for these processes is the slow diffusion through the dead keratinized horny layer of skin.^{10,11} Stratum corneum acts as a hydrophobic membrane. The rates of permeability of skin by low and high molecular weight organic non-electrolytes are mostly determined within the stratum corneum.^{12,13} The main interest in dermal absorption assessment is related to:¹

1. Local effects in dermatology¹⁴
2. Transport through the skin, seeking a systemic effect¹⁴
3. Surface effects^{15,16}
4. Targeting of deeper tissues^{17,18}
5. Unwanted absorption.^{19,20} Routes of drug penetration.¹

Transdermal drug delivery system (TDDS)

Transdermal drug delivery systems (TDDS) have been recently developed, aiming to achieve the objective of systemic medication through topical application to the intact skin surface.^{21,22} Transdermal therapeutic system is defined as self-contained individually separate dosage forms which, when applied to the intact skin, deliver the drug, through the skin at a controlled rate to the systemic circulation.²³ Transdermal delivery can provide a number of advantages including enhanced efficacy with increased safety and improved patient compliance. This route of drug administration avoids the hazards and disadvantages associated with parenteral therapy and improves patient compliance.²⁴ Transdermal route is an interesting option in this respect because transdermal route is convenient and safe.²⁵ Transdermal drug delivery system encounters the barrier properties of the dead keratinized horny layer (Stratum Corneum) and hence only the lipophilic drugs that have a molecular weight <500 Dalton can pass through it.²⁶ TDDS has some other therapeutic benefits such as sustained drug delivery to provide a steady state plasma profile and hence reduced systemic adverse effects, thus developing the potential for improved patient compliance. Avoid the bypass of first pass metabolism effect for drug having poor oral bioavailability.²⁷ In order to enhance drug transdermal absorption, different methodologies have been investigated, developed, and patented.^{28,29} Improvement in physical permeation enhancement technologies has led to renewed interest in transdermal drug delivery.¹ Some of these novel advanced transdermal permeation-enhancement technologies include iontophoresis, electroporation, ultrasound, microneedles to open up the skin, and more recently the use of transdermal nanocarriers,^{30,31,32} Now-a-days liposomes, niosomes, transferosomes

and ethosomes (vesicular and non- invasive drug delivery) are used to increase the permeation of drug through the stratum corneum.³³

Ethosomes

“Ethosomes are ethanolic Liposome”. Touitou invented a new vesicular system which was named ethosomes, due to the presence of ethanol in the vesicular structure.³⁴ Ethosomes were first developed by taitou & her colleagues in 1997.³⁵ Ethosomes can be defined as noninvasive delivery carriers that enable drugs to reach deep into the skin layers and/or the systemic circulation. These are soft, malleable vesicles tailored for enhanced delivery of active pharmaceutical ingredients(API). The Nano carrier vesicles have been well known for their importance in cellular communication extended time, keeping the drug shielded from immune response or other removal systems and thus be able to release just the exact amount of drug and keep that concentration constant for longer periods of time. One of the major advances in vesicle research was the finding of a vesicle derivative, known as an Ethosomes.^{36,37}

Benefits of Ethosomal drug Delivery System

Ethosomes includes a lots of benefits such as:

- Ethosomes are able to deliver various molecules like peptides, protein molecules, etc.
- Ethosomes are formulated by using biologically and eco- friendly chemicals rendering it non toxic to the human body.
- Ethosomal delivery is a exemplary option for transdermal delivery of medicament as it enhances the permeation.
- It can be implement to enormous fields like Cosmetic, Pharmaceutical, Veterinary fields.
- Ethosomal delivery can be formulated into gel or cream so as to generate high patient compliance.
- In contrast to various alternative techniques ethosomes are better technique.^{38,39,40}

Composition of Ethosome

The ethosomes may contain phospholipids with various chemical structures like phosphatidylcholine (PC), hydrogenated PC, phosphatidic acid (PA), phosphatidylserine (PS), phosphatidylethanolamine (PE), phosphatidylglycerol (PPG), phosphatidylinositol (PI), hydrogenated PC, alcohol (ethanol or isopropyl alcohol), water and propylene glycol (or other glycols). Ethosomal delivery system deliver medicament very efficiently across the skin membrane. Ethosomal vesicles can be prepared by varying the concentration of alcohol, propylene glycol and phospholipids. Mostly preferred phospholipid is soya lecithin (phosphatidylcholine). It is utilized in the concentration range of 0.5-10% w/w. Mostly preferred alcohols involves ethanol and isopropyl glycol. Cholesterol is also occasionally utilized in the preparation in the concentrations range of 0.1-1%. In expansion, the non ionic surfactants (PEG-alkyl ethers) are utilized along with the phospholipids. The alcohol concentration in final product is may be about 20 to 50%. The range of non- aqueous phase concentration (alcohol and glycol mixture) is may be about 22 to 70%.⁴¹




Fig. 2: Structure of Ethosomes.⁴²

Types of Ethosome

Classical Ethosome

They are slight modifications of the conventional liposomes first prepared by Touitou et al. composed of Phospholipids and a relatively high concentration of ethanol (up to 45%).^{42,43}

Binary Ethosome

They were first described by Zhou et al. [2]. They are just simple ethosomes the only difference between them and classical ethosomes is the type of alcohol, in classical ethosomes ethanol is the only alcohol used but in binary ethosomes alcohol used are propylene glycol(PG) and isopropyl alcohol(IPA).⁴⁴

Transethosome

Transethosomes are a new generation of vesicular ethosomal systems first described by Song et al. [3] in 2012 for efficient delivery of the drug across skin as they combine the advantages of classical ethosomes and deformable liposomes (transferosomes).⁴⁵

Table 1. Different additives employed In formulation of ethosomes⁴²

Material	Examples	Uses
Phospholipid	Soya phosphatidyl choline Egg phosphatidyl choline Dipalmityl phosphatidyl choline Distearyl phosphatidyl choline	Vesicles forming component
Polyglycol	Propylene glycol Transcutol RTM	As a skin penetration enhancer
Alcohol	Ethanol Isopropyl alcohol	For providing the softness for vesicle membrane As a penetration enhancer
Cholesterol	Cholesterol	For providing the stability to vesicle membrane
Dye	Rhodamine-123 Rhodamine red Fluorescen Isothiocynate (FITC) 6-Carboxy fluorescence	For characterization study
Vehicle	Carbopol 934	As a gel former

Methods of preparations of Ethosomes

Ethosomal formulation may be prepared by hot or cold method as described below. Both the methods are convenient, do not require any sophisticated equipment and are easy to scale up at industrial level.

Cold Method

In this method Phospholipids, drug and other lipid materials are dissolved in ethanol in a covered vessel at room temperature by vigorous stirring with the use of mixer. Propylene glycol or other polyol is added during stirring. This mixture is heated to 30°C in a water bath. The water heated to 30°C in a separate vessel is added to the mixture, which is then stirred for 5 min in a covered vessel. The vesicle size of ethosomal formulation can be decreased to the desire extent using probe sonication or extrusion method. Finally, the formulation is stored under refrigeration.^{46,47}




Fig. 3: Formulation method of ethosomes by cold method.^{48,49,50,51}

Hot Method

This method was first used by Touitou [7] in 1996 in this method phospholipid is dispersed in water by heating it in a water bath at 40°C until a colloidal solution is obtained. In a separate vessel, ethanol and propylene glycol are mixed and heated to 40°C. Once both mixtures reach 40°C, the organic phase is added to the aqueous phase. The drug is dissolved in ethanol or water based on its hydrophilic/hydrophobic properties. The vesicle size of the ethosomal formulation can be modified to the desired extent using probe sonication or extrusion method.⁴²




Figure 4: Hot Method for Preparation of Ethosomes.^{52,53}

Mechanism of Drug Penetration

The main advantage of ethosomes over liposomes is the increased permeation of the drug. The mechanism of the drug absorption from ethosomes is not clear. The drug absorption probably occurs in following two phases:

- Ethanol effect
- Ethosomes effect



1. Ethanol effect

Ethanol acts as a penetration enhancer through the skin. The mechanism of its penetration enhancing effect is well known. Ethanol penetrates into intercellular lipids and increases the fluidity of cell membrane lipids and decrease the density of lipid multilayer of cell membrane.

2. Ethosomes effect


Ethosome Increased cell membrane lipid fluidity caused by the ethanol results increased skin permeability. So the ethosomes permeates very easily inside the deep skin layers, where it got fused with skin lipids and releases the drugs into deep layer of skin.^{37,54}

Fig:5 & 6 Mechanism action of Ethosome for Transdermal drug delivery system.^{48, 55,56}



SAFETY OF ETHOSOMAL SYSTEMS

Ethosomes are composed of ingredients generally regarded as safe (GRAS). The safety of ethosomal systems applied topically to the skin has been tested in numerous works, both *in vitro* and *in vivo*. *In vitro* studies on cell cultures showed that ethosomal systems are safe to skin cells.^{57,58,59}



Conclusion

Ethosome nano vesicular carrier open new challenge and opportunities for the development of Transdermal drug delivery system. Ethosome create alternative route for TDDS over the drug delivery for systemic effect. It can be easily concluded that ethosomes can provide better skin permeation than liposomes. The main limiting factor of transdermal drug delivery system i.e. Stratum corneum barrier can be overcome by Ethosomes. Ethosomes are more advantages when compared to transdermal and dermal drug delivery system. They are the noninvasive drug delivery carriers that enable drugs to reach the deep skin layers (Stratum Corneum) finally delivering to the systemic circulation. It delivers large molecules such as peptides, protein molecules. Ethosomes are characterized by simplicity in their preparation, safety and efficacy and can be tailored for enhanced skin permeation of active drugs. Continuous research in ethosomal technology has led to the introduction of a new generation of the ethosomal system called transethosomes which are the updated version of classical ethosomes in terms of vesicle properties and skin permeation abilities.

Reference

1. Escobar-Chávez, Josá & Díaz-Torres, Roberto & Rodríguez Cruz, Isabel & Domínguez-Delgado, Clara & R, Sampere & Angeles, Enrique & Melgoza, Luz. (2012). Nanocarriers for transdermal drug delivery. *Research and Reports in Transdermal Drug Delivery*. 2012:1. 3. 10.2147/RRTD.S32621.
2. Escobar Chávez JJ, Merino-Sanjuan V, López-Cervantes M, et al. The tape-stripping technique as a method for drug quantification in skin. *J Pharm Pharmaceut Sci*. 2008;11:104–130(23,36r)
3. Potts RO, Guy RH. Predicting skin permeability. *Pharm Res*. 1992;9:663–669.
4. Jain, H., Patel, J., Joshi, K., Patel, P. and Upadhyay, U., 2011. ETHOSOMES: A NOVEL DRUG CARRIER. *Pharmacie Globale (IJCP)*, 7(01).
5. Scheuplein R J, Blank I H; Permeability of the skin. *Physiol Rev*. 1971; 51(4):702-747.
6. Barry B W; In *Dermatological Preparations: Percutaneous Absorption*. Marcel Dekker Inc. New York. 1983;18:1-48.
7. Katz M, Poulsen B J; In *Handbook of Experimental Pharmacology*. Broie B B, Gillette J R. Eds. Springer- Verlag, Berlin, 1971; 27:103-174.
8. Holbrook K A, Odland G E; Regional differences in the thickness (cell layer) of human stratum corneum: an ultrastructure analysis. *J Invest Dermatol*. 1974; 62: 415-422.
9. Menton D N, Eisen A Z; Structure and organization of mammalian stratum corneum. *J Ultrastructure Res*. 1971; 35:247-264.
10. Flynn G L; In *Principles of route-to-route extrapolation for risk assessment*. Gerrity T R, Henry C J. Eds. Elsevier Science Publishing Co. Inc. New York, 1990; 93-127.
11. Flynn G L, Durrheim H, Higuchi I W; Permeation of hairless mouse skin II: Membrane sectioning techniques and influence on alkanol permeability. *J Pharm Sci*. 1981; 70:2-56.
12. Roy S D, Flynn G H; Transdermal delivery of narcotic analgesics: Comparative permeabilities of narcotic analgesics through human cadaver skin. *Pharm Res*. 1989; 6:825-832.
13. Wertz P W, Downing D T; In *Transdermal Drug Delivery, Development Issues and Research Initiatives*, Hadgraft, J J, Guy R H. Eds. Marcel Dekker Inc, New York. 1989;35:1-22.
14. Escobar-Chávez JJ, Merino V, Díez-Sales O, et al. Transdermal nortriptyline hydrochloride patch formulated within a chitosan matrix intended to be used for smoking cessation. *Pharm Dev Technol*. 2011;16:162–169.

15. Escobar-Chávez JJ, López-Cervantes M, Naik A, Kalia YN, QuintanarGuerrero D, Ganem Quintanar A. Applications of the thermoreversible Pluronic F-127 gels in pharmaceutical formulations. *J Pharm Pharmaceut Sci.* 2006;9:339–358.
16. Domínguez-Delgado CL, Rodríguez-Cruz IM, Escobar-Chávez JJ, Calderón-Lojero IO, Quintanar-Guerrero D, Ganem A. Preparation and characterization of triclosan nanoparticles intended to be used for the treatment of acne. *Eur J Pharm Biopharm.* 2011;79:102–107.
17. Fang JY, Leu YL, Wang YY, Tsai YH. In vitro topical application and in vivo pharmacodynamic evaluation of nonivamide hydrogels using Wistar rat as an animal model. *Eur J Pharm Sci.* 2002;15:417–423.
18. Wang YY, Hong CT, Chiu WT, Fang JY. In vitro and in vivo evaluations of topically applied capsaicin and nonivamide from hydrogels. *Int J Pharm.* 2000;224:1–2.
19. Mattorano DA, Kupper LL, Nylander-French LA. Estimating dermal exposure to jet fuel (naphthalene) using adhesive tape strip samples. *Ann Occup Hyg.* 2004;48:139–146.
20. Chao YC, Nylander-French LA. Determination of keratin protein in a tape-stripped skin sample from jet fuel exposed skin. *Ann Occup Hyg.* 2004;48:65–73.
21. Ethosomes: A Novel Approach in Transdermal Drug Delivery System Neeraj Kumar*, Anubhav Dubey, Ashish Mishra and Pallavi Tiwari. Review Article ISSN: 0976-7126 CODEN (USA): IJPLCP Kumar et al., 11(5):6598-6608, 2020.
22. Chien Yiew: Novel Drug Delivery System. Revised And Expanded Informa Healthcare. 2009;50:301-3022.
23. Jain NK. Controlled and Novel Drug Delivery. 1sted. CBS Publisher & Distributors 1997;1:100-101.
24. Vyas SP. Khar Roop.K. Controlled Drug Delivery Concepts and Advances. 1sted. Vallabh Prakashan 2002;1:412-413.
25. Jain NK. Advance in Controlled and Novel Drug Delivery. 1sted. CBS Publishers & Distributors 2001;1:426.
26. Satnam Singh and Sandeep Kumar. Ethosomes a new pathway for novel drug delivery. *Indo American Journal of Pharmaceutical Sciences* 2018;5:7552-7559.
27. 6. Viswanad Vidya, PG Anju, Kumar Gopika S, Nair Sivapriya G. Formulation development and invitro characterisation of ethosomes for the enhanced transdermal delivery of clotrimazole. *International Journal of Research in Pharmaceutical Sciences* 2019;10:874-882.
28. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. *Eur J Pharm Sci.* 2001;14:101–104.
29. Rizwan M, Aqil M, Talegaonkar S, Azeem A, Sultana Y, Ali A. Enhanced transdermal drug delivery techniques: an extensive review of patents. *Recent Pat Drug Deliv Formul.* 2009;3:105–124.
30. Díaz-Torres R. Transdermal nanocarriers. In: Escobar-Chávez JJ, Merino V, editors. *Current Technologies to Increase the Transdermal Delivery of Drugs.* Bussum: Bentham Science; 2010:120–140.
31. 8. Escobar-Chávez JJ, Merino V, editors. *Current Technologies to Increase the Transdermal Delivery of Drugs.* Bussum: Bentham Science; 2010.
32. Escobar-Chávez JJ, Bonilla-Martínez D, Villegas-González A, Revilla-Vazquez AL. Electroporation as an efficient physical enhancer for transdermal drug delivery. *J Clin Pharmacol.* 2009;49: 1262–1283.
33. Kumar Ananda.Ch, Dutt Dr. Rajeswar. Ethosomes a novel transdermal drug delivery system. *World Journal of Pharmaceutical Research* 2014;3:3740-3750.

34. Touitou E, Godin B. Ethosomes for skin delivery. *Journal of Drug Delivery Science and Technology* 2007;17:303-308.
35. Patel Ravi b, Patel Tejas B, Suhagia B.N, Patel Mehul N, Patel Mayur, and Patel Parth. Ethosomes an emerging targeted drug delivery system a review. *International Journal of Pharmaceutical Sciences and Research* 2014;2:941-961.
36. Manosroi A., Jantrawut P., Khositsuntiwong N., Manosroi W., Manosroi J., Novel Elastic Nano vesicles for Cosmeceutical and Pharmaceutical Applications, *Chiang Mai Journal of Science* 2009;36,2:168-178.
37. Ethosomes: A review **Divya * et al./** *Int. J. Pharm. Med. Res.* 2016; 4(4):354-363
38. S. Agarwal et al. *Int. Res. J. Pharm.* 2019, 10, Ethosome an advanced approach of TDDS.
39. Gangwar S, Singh S, Garg G. Ethosomes: A Novel Tool for Drug Delivery Through the Skin. *Journal of Pharmacy Research* 2010; 3(4):688-691.
40. Sivakranth M, AnjumaAra P, Krishnaveni C, Venkatesh E. Ethosomes: A Novel Vesicular Drug Delivery System. *International Journal of Advances in Pharmaceutical Research* 2012; 2(1):16-27.
41. Leigh C. Anti-aging products for skin, hair and nails: How vitamins, antioxidants and fruit acids keep people looking young. *Issue of Nutrition Science News. Indian Pharmacopoeia. Controller of Publication* 2000 ; Volume- 1:281.
42. Aggarwal R & Sahoo PK, *Sch. Acad. J. Pharm.*, Jun 2018; 7(6): 266-273, Ethosome : the novel drug carries.
43. Touitou E, Godin B, Dayan N, Weiss C, Piliponsky A, Levi-Schaffer F. Intracellular delivery mediated by an ethosomal carrier. *Biomaterials.* 2001 Nov 15;22(22):3053-9.
44. Zhou Y, Wei Y, Liu H, Zhang G, Wu XA. Preparation and in vitro evaluation of ethosomal total alkaloids of *Sophora alopecuroides* loaded by a transmembrane pH-gradient method. *Aaps Pharmscitech.* 2010 Sep 1;11(3):1350-8.
45. Song CK, Balakrishnan P, Shim CK, Chung SJ, Chong S, Kim DD. A novel vesicular carrier, transethosome, for enhanced skin delivery of voriconazole: characterization and in vitro/in vivo evaluation. *Colloids and Surfaces B: Biointerfaces.* 2012 Apr 1;92:299-304.
46. Pravin P. Aute et. al., December - January, 2012-13, 2(1), 218-224, A Comprehensive review of ethosome.
47. Williams ML, Elias PM. The extracellular matrix of stratum corneum: role of lipids in normal and pathological function. *Crit rev Therapy drug carrier Systems* (1987) 3: 95-122.
48. Mistry et al., *IJPSR*, 2015; Vol. 6(10): 4129-4136, ETHOSOMES: unique vasicular carrier.
49. Nikalje P, Tiwari S. Ethosomes: A Novel Tool for Transdermal Drug Delivery. *IJRPS International Journal of Research in Pharmacy and Science* 2012; 2(1):1-20.
50. Keerthi A, Srujan Kumar M, Dr Subrahmanyam K.V. Formulation of Ethosomal Gel for Transdermal Delivery of Tramadol Hydrochloride. *International Journal of Innovative Pharmaceutical Sciences and Research* 2013; 1(2): 281-295.
51. Touitou E. Compositions for applying active substances to or through the skin. US5540934 A. 1996.
52. Pakhale NV, Gondkar SB, Saudagar RB, Ethosomes: Transdermal Drug Delivery System, *Journal of Drug Delivery and Therapeutics.* 2019; 9(3):729.
53. Aggrawal D, Nautiyal U, "Ethosomes: A review", *International Journal of Pharmaceutical and medicinal Research* 201; 4(4):354-363.
54. Heeremans JLM., Gerristen HR., Meusen SP., Mijnheer FW., Gangaram RS., Panday G., Prevost R., Kluft C., Crommelin DJA., The preparation of Tissue Type Plasminogen Activator (T- PA) containing liposomes: Entrapment Efficacy and Ultracentrifugation Damage, *Journal of Drug Targeting* 1995;3:301.
55. B. Godin and E. Touitou, Erythromycin ethosomal systems: Physicochemical characterization and enhanced antibacterial activity. *Curr. Drug Deliv.* 2, 269 (2005).
56. V. Pandey et al. *Drug Delivery*, 2015; 22(8): 988-1002 Ethosomes: versatile vesicular carriers for efficient transdermal delivery of therapeutic agents.

57. J. Biomed. Nanotechnol. 2010, Vol. 6, No. 5 J. Biomed. Nanotechnol. 2010, Vol. 6, No. 5
doi:10.1166/jbn.2010.1152 .

58 B. Godin and E. Touitou, Erythromycin ethosomal systems: Physicochemical characterization and enhanced antibacterial activity. *Curr. Drug Deliv.* 2, 269 (2005).

59. E. Touitou, B. Godin, N. Dayan, C. Weiss, A. Piliponsky, and
F. Levi-Schaffer, Intracellular delivery mediated by an ethosomal carrier. *Biomaterials* 22, 3053 (2001).

